| 5.92 -0.02 (-0.34%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.7  |
1-year : | 8.37 |
| Resists | First : | 6.6 |
Second : | 7.17 |
| Pivot price | 6.02 |
|||
| Supports | First : | 5.67 | Second : | 4.72 |
| MAs | MA(5) : | 5.98  |
MA(20) : | 6.18 |
| MA(100) : | 6.59 |
MA(250) : | 8.24 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 26.4 |
D(3) : | 27.8 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 12.93 | Low : | 4.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LNSR ] has closed above bottom band by 37.7%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.98 - 6.02 | 6.02 - 6.05 |
| Low: | 5.75 - 5.8 | 5.8 - 5.84 |
| Close: | 5.86 - 5.93 | 5.93 - 5.98 |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Tue, 27 Oct 2026
Price-Driven Insight from (LNSR) for Rule-Based Strategy - Stock Traders Daily
Mon, 26 Oct 2026
LENSAR, Inc. Estimates – BOATS:LNSR - TradingView
Fri, 23 Oct 2026
People to Know in Healthcare: Nick Curtis, Lensar - The Business Journals
Fri, 14 Aug 2026
Lensar Returns to Profit in Q2 on Strong Demand for ALLY Cataract System - VisionMonday.com
Thu, 13 Aug 2026
LENSAR, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Thu, 13 Aug 2026
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 12 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 21.5 (%) |
| Held by Institutions | 45.9 (%) |
| Shares Short | 322 (K) |
| Shares Short P.Month | 382 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 57.5 % |
| Operating Margin | 12.9 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | 357.2 % |
| Qtrly Rev. Growth | 18.3 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 4.9 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | 32.88 |
| PEG Ratio | 0 |
| Price to Book value | 4.89 |
| Price to Sales | 1.2 |
| Price to Cash Flow | -9.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|